{{Drugbox
| verifiedrevid = 460111355
| IUPAC_name = 4-(5''H''-dibenzo [a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride
| image = Cyproheptadine.svg
| width = 170
| image2 = Cyproheptadine-Spartan-PM3-3D-balls.png
| width2 = 140

<!--Clinical data-->
| tradename = Periactin
| Drugs.com = {{drugs.com|monograph|cyproheptadine-hydrochloride}}
| MedlinePlus = a682541
| pregnancy_US = B
| legal_UK = P
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| protein_bound = 96 to 99%
| metabolism = [[Liver|Hepatic]] and [[kidney|renal]]
| elimination_half-life = 8.6 hours<ref name="pmid15083941">{{cite journal | author = Gunja N, Collins M, Graudins A | title = A comparison of the pharmacokinetics of oral and sublingual cyproheptadine | journal = Journal of Toxicology. Clinical Toxicology | volume = 42 | issue = 1 | pages = 79–83 | year = 2004 | pmid = 15083941 | doi = | url = }}</ref>
| excretion = Fecal and renal

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 129-03-3
| CAS_supplemental = 969-33-5 ([[hydrochloride]])
| ATC_prefix = R06
| ATC_suffix = AX02
| PubChem = 2913
| IUPHAR_ligand = 277
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00434
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2810
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2YHB6175DO
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07765
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4046
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 516

<!--Chemical data-->
| C = 21 | H = 21 | N = 1 
| molecular_weight = 287.398 g/mol
| smiles = c43\C(=C1/CCN(C)CC1)c2ccccc2\C=C/c3cccc4
| InChI = 1/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
| InChIKey = JJCFRYNCJDLXIK-UHFFFAOYAW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JJCFRYNCJDLXIK-UHFFFAOYSA-N
}}

'''Cyproheptadine''' ({{IPAc-en|icon|ˌ|s|aɪ|p|r|ɵ|ˈ|h|ɛ|p|t|ə|d|iː|n}}), sold under the brand name '''Periactin''', is a [[first-generation antihistamine|first-generation]] [[antihistamine]] with additional [[anticholinergic]], [[antiserotonergic]], and [[local anesthetic]] properties.

== Indications ==
[[File:Periactin.jpg|thumb|Periactin (cyproheptadine) 4 mg tablets]]

* Cyproheptadine is used to treat allergic reactions (specifically [[hay fever]]).<ref>[http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682541.html MedlinePlus Drug Information: Cyproheptadine]</ref>

* Has shown effectiveness in the treatment of [[nightmares]] including nightmares related to [[post traumatic stress disorder]].<ref>{{ cite journal |pmid=10964879 |url=http://ajp.psychiatryonline.org/cgi/content/full/157/9/1524-a |doi=10.1176/appi.ajp.157.9.1524-a |title=Cyproheptadine for Posttraumatic Nightmares |year=2000 |author=Rijnders, R. J.P. |journal=American Journal of Psychiatry |volume=157 |pages=1524–a |last2=Laman |first2=DM |last3=Van Diujn |first3=H |issue=9 }}</ref><ref>{{ cite journal |pmid=9606583 |year=1998 |month=May |author=Gupta, S; Popli, A; Bathurst, E; Hennig, L; Droney, T; Keller, P |title=Efficacy of cyproheptadine for nightmares associated with posttraumatic stress disorder |volume=39 |issue=3 |pages=160–4 |issn=0010-440X |journal=Comprehensive Psychiatry |doi=10.1016/S0010-440X(98)90076-1 }}</ref>

* Has been used in the management of moderate to severe cases of [[serotonin syndrome]] (a complex of symptoms associated with the use of [[serotonergic]] drugs, such as [[selective serotonin reuptake inhibitor]]s and [[monoamine oxidase inhibitors]]),<ref>{{cite journal |author=Mills KC |title=Serotonin syndrome |journal=American Family Physician |volume=52 |issue=5 |pages=1475–82 |year=1995 |month=October |pmid=7572570}}</ref><ref>{{cite journal |doi=10.1177/026988119901300111 |author=Gillman PK |title=The serotonin syndrome and its treatment |journal=Journal of Psychopharmacology (Oxford, England) |volume=13 |issue=1 |pages=100–9 |year=1999 |pmid=10221364}}</ref><ref>{{cite journal |author=Hall M, Buckley N |title=Serotonin syndrome |journal=Australian Prescriber |volume=26 |issue=3 |pages=62–3 |year=2003 |url=http://www.australianprescriber.com/magazine/26/3/62/3}}</ref> and in cases of hyperserotoninaemia resulting from a serotonin producing [[carcinoid]] tumour <ref name="pmid4274414">{{cite journal |author=Berry EM, Maunder C, Wilson M |title=Carcinoid myopathy and treatment with cyproheptadine (Periactin) |journal=Gut |volume=15 |issue=1 |pages=34–8 |year=1974 |month=January |pmid=4274414 |pmc=1412931 |doi= 10.1136/gut.15.1.34|url=http://gut.bmj.com/cgi/pmidlookup?view=long&pmid=4274414}}</ref><ref name=Moertel1991>{{cite journal | author = Moertel, Charles G. | year = 1991 | title = A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome | journal = Cancer | volume = 67 | pages = 33–6 | doi = 10.1002/1097-0142(19910101)67:1<33::AID-CNCR2820670107>3.0.CO;2-E | url = http://www3.interscience.wiley.com/journal/112674381/abstract | pmid = 1985720 | last2 = Kvols | first2 = LK | last3 = Rubin | first3 = J | issue = 1}}</ref>

* Can also be used as a preventive measure against [[migraine]] in children and adolescents.<ref>{{cite web |author=Wendy G Mitchell et al. |url=http://www.emedicine.com/neuro/TOPIC494.HTM |title=Childhood Migraine Variants |work= |accessdate= |year=2006}}</ref><ref>[http://www.healthsystem.virginia.edu/internet/neurogram/neurogram3_4_peds_migraines.cfm UVA Neurogram: Treatment of Pediatric Migraine]</ref><ref>[http://www.netdoctor.co.uk/medicines/100002043.html Netdoctor: Periactin]</ref><ref>[http://my.clevelandclinic.org/disorders/Migraine_Headache/hic_Migraines_in_Children_and_Adolescents.aspx Migraines in Children and Adolescents]</ref><ref>{{cite journal |author=Klimek A |title=Cyproheptadine (Peritol) in the treatment of migraine and related headache |journal=Ther Hung |volume=27 |issue=2 |pages=93–4 |year=1979 |pmid=494146 |doi= |url=}}</ref>

* Can relieve [[Selective_serotonin_reuptake_inhibitor#Sexual_dysfunction|SSRI-induced sexual dysfunction]]<ref>{{cite journal |author=Keller Ashton A, Hamer R, Rosen RC |title=Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients |journal=Journal of Sex & Marital Therapy |volume=23 |issue=3 |pages=165–75 |year=1997 |pmid=9292832 |doi= 10.1080/00926239708403922|url=}}</ref><ref>{{cite journal |author=McCormick S, Olin J, Brotman AW |title=Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients |journal=[[Journal of Clinical Psychiatry]] |volume=51 |issue=9 |pages=383–4 |year=1990 |month=September |pmid=2211550 |doi= |url=}}</ref> and drug-induced [[hyperhidrosis]] (excessive sweating).<ref>{{cite journal |author=Ashton AK, Weinstein WL |title=Cyproheptadine for drug-induced sweating |journal=[[American Journal of Psychiatry]] |volume=159 |issue=5 |pages=874–5 |year=2002 |month=May |pmid=11986151 |doi= 10.1176/appi.ajp.159.5.874-a|url=http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=11986151}}</ref> 

* Also used in the treatment of [[cyclical vomiting syndrome]]<ref>{{cite journal |author=Andersen JM, Sugerman KS, Lockhart JR, Weinberg WA |title=Effective Prophylactic Therapy for Cyclic Vomiting Syndrome in Children Using Amitriptyline or Cyproheptadine |journal=[[Pediatrics]] |volume=100 |issue=6 |pages= 977–981 |year=1997 |month=December |pmid=9374568 |url=http://pediatrics.aappublications.org/cgi/content/abstract/100/6/977 |doi=10.1542/peds.100.6.977}}</ref> 

*A long term use of the drug can stimulate the [[appetite]] and may lead to [[weight gain]], which is helpful for [[underweight]] people.<ref>[http://onlinelibrary.wiley.com/doi/10.1002/ppul.20265/abstract Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis | Wiley Online Library]</ref>

* According to a small study, cyproheptadine hydrochloride has been found to improve sleep, calmness and negative symptoms in chronic [[schizophrenia|schizophrenics]] who do not respond to other therapies.<ref>{{cite web|url=http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3048|title=Cyproheptadine, Human Health Effects|publisher=Toxicology Data Network|date=2003|accessdate=8 November 2012}}</ref>

== Pharmacology ==
Cyproheptadine is known to be an [[receptor antagonist|antagonist]] (or [[inverse agonist]] depending on the site in question) of the following [[receptor (biochemistry)|receptor]]s, listed in order of [[potency (pharmacology)|potency]] from greatest to least (K<sub>i</sub>):

* [[H1 receptor|H<sub>1</sub>]] (~0.05 nM)<ref name="pmid7925364">{{cite journal | author = Moguilevsky N, Varsalona F, Noyer M, ''et al.'' | title = Stable expression of human H1-histamine-receptor cDNA in Chinese hamster ovary cells. Pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene | journal = European Journal of Biochemistry / FEBS | volume = 224 | issue = 2 | pages = 489–95 | year = 1994 | month = September | pmid = 7925364 | doi = 10.1111/j.1432-1033.1994.00489.x| url = http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0014-2956&date=1994&volume=224&issue=2&spage=489}}</ref> > [[5-HT2A receptor|5-HT<sub>2A</sub>]] (~2 nM)<ref name="pmid2898916">{{cite journal | author = Peroutka SJ | title = Antimigraine drug interactions with serotonin receptor subtypes in human brain | journal = Annals of Neurology | volume = 23 | issue = 5 | pages = 500–4 | year = 1988 | month = May | pmid = 2898916 | doi = 10.1002/ana.410230512 | url = }}</ref> ≈ [[5-HT2B receptor|5-HT<sub>2B</sub>]] (~1.5 nM)<ref name="pmid9225287">{{cite journal | author = Bonhaus DW, Weinhardt KK, Taylor M, ''et al.'' | title = RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist | journal = Neuropharmacology | volume = 36 | issue = 4–5 | pages = 621–9 | year = 1997 | pmid = 9225287 | doi = 10.1016/S0028-3908(97)00049-X| url = }}</ref> ≈ [[5-HT2C receptor|5-HT<sub>2C</sub>]] (~2 nM)<ref name="pmid9225287" /> > [[muscarinic acetylcholine receptor|mACh]] ([[muscarinic acetylcholine receptor M1|M<sub>1</sub>]]-[[muscarinic acetylcholine receptor M5|M<sub>5</sub>]]; ~7-12 nM)<ref name="pmid8100134">{{cite journal | author = Stanton T, Bolden-Watson C, Cusack B, Richelson E | title = Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics | journal = [[Biochemical Pharmacology]] | volume = 45 | issue = 11 | pages = 2352–4 | year = 1993 | month = June | pmid = 8100134 | doi = 10.1016/0006-2952(93)90211-E| url = }}</ref> ≈ [[D3 receptor|D<sub>3</sub>]] (~8 nM)<ref name="pmid9686407">{{cite journal | author = Toll L, Berzetei-Gurske IP, Polgar WE, ''et al.'' | title = Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications | journal = NIDA Research Monograph | volume = 178 | issue = | pages = 440–66 | year = 1998 | month = March | pmid = 9686407 | doi = | url = }}</ref>

It also has weak but likely negligible [[affinity (pharmacology)|affinity]] for the following sites (K<sub>i</sub>):

* [[5-HT1A receptor|5-HT<sub>1A</sub>]] (~60-100 nM)<ref name="pmid2898916" /><ref name="pmid9686407" /> ≈ [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic]] (?? nM)<ref name="Dukhovich2005">{{cite book | author = F. S. Dukhovich | title = Pharmacological aspects of molecular recognition | url = http://books.google.com/books?id=9hvuXVPepMQC&pg=PA117 | accessdate = 27 November 2011 | date = 15 August 2005 | publisher = Nova Publishers | isbn = 978-1-59454-676-1 | page = 117}}</ref> ≈ [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic]] (?? nM)<ref name="Dukhovich2005" /> > [[5-HT6 receptor|5-HT<sub>6</sub>]] (~135-150 nM)<ref name="pmid8522988">{{cite journal | author = Kohen R, Metcalf MA, Khan N, ''et al.'' | title = Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor | journal = Journal of Neurochemistry | volume = 66 | issue = 1 | pages = 47–56 | year = 1996 | month = January | pmid = 8522988 | doi = 10.1046/j.1471-4159.1996.66010047.x| url = http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0022-3042&date=1996&volume=66&issue=1&spage=47}}</ref><ref name="pmid8226867">{{cite journal | author = Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL | title = Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase | journal = The Journal of Biological Chemistry | volume = 268 | issue = 31 | pages = 23422–6 | year = 1993 | month = November | pmid = 8226867 | doi = | url = http://www.jbc.org/cgi/pmidlookup?view=long&pmid=8226867}}</ref> ≈ [[5-HT7 receptor|5-HT<sub>7</sub>]] (~125 nM)<ref name="pmid8226867" /> ≈ [[D1 receptor|D<sub>1</sub>]] (~115 nM)<ref name="pmid9686407" /> ≈ [[D2 receptor|D<sub>2</sub>]] (~115 nM)<ref name="pmid9686407" /> > [[5-HT3 receptor|5-HT<sub>3</sub>]] (~250 nM)<ref name="pmid9686407" /><ref name="pmid3352595">{{cite journal | author = Hoyer D, Neijt HC | title = Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding | journal = Molecular Pharmacology | volume = 33 | issue = 3 | pages = 303–9 | year = 1988 | month = March | pmid = 3352595 | doi = | url = http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=3352595}}</ref> ≈ [[Norepinephrine transporter|NET]] (~300 nM)<ref name="pmid11266163">{{cite journal | author = Runyon SP, Savage JE, Taroua M, Roth BL, Glennon RA, Westkaemper RB | title = Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene | journal = Bioorganic & Medicinal Chemistry Letters | volume = 11 | issue = 5 | pages = 655–8 | year = 2001 | month = March | pmid = 11266163 | doi = 10.1016/S0960-894X(01)00023-3| url = http://linkinghub.elsevier.com/retrieve/pii/S0960894X01000233}}</ref>

Additionally, cyproheptadine possesses [[calcium channel blocker|calcium channel-blocking]]<ref name="pmid6271323">{{cite journal | author = Lowe DA, Matthews EK, Richardson BP | title = The calcium antagonistic effects of cyproheptadine on contraction, membrane electrical events and calcium influx in the guinea-pig taenia coli | journal = [[British Journal of Pharmacology]] | volume = 74 | issue = 3 | pages = 651–63 | year = 1981 | month = November | pmid = 6271323 | pmc = 2071752 | doi = | url = }}</ref> and [[local anesthetic]] properties.<ref name="pmid428422">{{cite journal | author = Riccioppo Neto F | title = The local anesthetic effect of cyproheptadine on mammalian nerve fibres | journal = European Journal of Pharmacology | volume = 54 | issue = 3 | pages = 203–7 | year = 1979 | month = March | pmid = 428422 | doi = 10.1016/0014-2999(79)90078-5| url = }}</ref>

== Pharmacokinetics ==
Cyproheptadine is well-absorbed following oral ingestion, with peak plasma levels occurring after 1-3 hours.<ref name="MurrayDaly2011">{{cite book | author1 = Lindsay Murray | author2 = Frank Daly | author3 = David McCoubrie | coauthors = Mike Cadogan | title = Toxicology Handbook | url = http://books.google.com/books?id=KDOeIldGWxQC&pg=PT388 | accessdate = 27 November 2011 | date = 15 January 2011 | publisher = Elsevier Australia | isbn = 978-0-7295-3939-5 | page = 388}}</ref> Its half-life when taken orally is approximately 8 hours.<ref name="pmid15083941" />

== Adverse effects ==
While not specifically used as a [[sedative]], cyproheptadine causes drowsiness,<ref name=Lexi-Comp>{{cite web |url=http://www.merck.com/mmpe/lexicomp/cyproheptadine.html |title=Cyproheptadine |date=August 2008 |author=Lexi-Comp |work=[[Merck Manual of Diagnosis and Therapy|The Merck Manual Professional]]}} Retrieved on October 26, 2008.</ref> as is common with first-generation antihistamines.

Research has shown a suppression of [[growth hormone]] with doses of 8–12&nbsp;mg per day taken for 5 days.<ref>{{cite journal |author=Rosskamp RH, Haverkamp F, von Kalckreuth G |title=The effect of cyproheptadine on plasma growth hormone (GH) and on somatostatin response to GH-releasing hormone in man |journal=Horm. Metab. Res. |volume=22 |issue=5 |pages=295–7 |year=1990 |month=May |pmid=1971804 |doi= 10.1055/s-2007-1004905|url=}}</ref>

Other common side effects include:<ref>[http://www.drugs.com/cdi/cyproheptadine.html ''Cyproheptadine - Drugs.com'']</ref>

* Dizziness
* Blurred vision
* Constipation
* Dry mouth, throat, or nose
* Excitability
* Nausea
* Nervousness
* Restlessness

== Veterinary use ==
Cyproheptadine is used in [[cat]]s as an appetite stimulant and as an adjunct in the treatment of [[asthma]].<ref name=MVM1>{{cite book |author= Dowling PM |chapter= Drugs Affecting Appetite |chapterurl= http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/190302.htm |editor= Kahn CM, Line S, Aiello SE (eds.) |title= [[Merck Veterinary Manual|The Merck Veterinary Manual]] |date= February 8, 2005 |publisher= [[John Wiley & Sons]] |edition= 9th |isbn= 0-911910-50-6}} Retrieved on October 26, 2008.</ref><ref name=MVM2>{{cite book |author= Dowling PM |chapter= Systemic Therapy of Airway Disease: Cyproheptadine |chapterurl=http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/190907.htm |editor= Kahn CM, Line S, Aiello SE (eds.) |title= The Merck Veterinary Manual |date= February 8, 2005 |publisher= [[John Wiley & Sons]] |edition= 9th |isbn= 0-911910-50-6}} Retrieved on October 26, 2008.</ref> Possible adverse effects include excitement and aggressive behavior.<ref name=MVM1/>  The [[elimination half-life]] of cyproheptadine in cats is 12 hours.<ref name=MVM2/> 

Cyproheptadine has been used successfully in treatment of Pituitary Pars Intermedia Dysfunction (PPID) in horses. <ref>{{cite web|last=Merck Vet Manual|title=Hirsutism Associated with Adenomas of the Pars Intermedia|url=http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/40504.htm|accessdate=April 24, 2011}}</ref>

== References ==
{{Reflist|2}}

{{Sedatives}}
{{Orexigenics}}
{{Adrenergics}}
{{Channel blockers}}
{{Cholinergics}}
{{Dopaminergics}}
{{Histaminergics}}
{{Serotonergics}}
{{Tricyclics}}

[[Category:Serotonin antagonists]]
[[Category:Piperidines]]
[[Category:Dibenzocycloheptenes]]
[[Category:H1 receptor antagonists]]